학술논문
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial
Document Type
Article
Author
François, B.; Lambden, S.; Derive, M.; Salcedo-Magguilli, M.; Hicheur, T.; Garaud, J.-J.; Cuvier, V.; Fivez, T.; Gibot, S.; Grouin, J.-M.; Lemarié, J.; De Schryver, N.; Jalkanen, V.; Ferrer, R.; Bestle, M.; Pettilä, V.; Mira, J.-P.; Bouisse, C.; Mercier, E.; Vermassen, J.; Huberlant, V.; Vinatier, I.; Anguel, N.; Levy, M.; Laterre, P.-F.; Asfar, P.; Nay, M.-A.; Guitton, C.; Quenot, J.-P.; Tran-Van, D.; Bohe, J.; Plantefève, G.; Nseir, S.; Lefrant, J.-Y.; Monnet, X.; Papazian, L.; Vinsonneau, C.; Constantin, J.-M.; Mebazaa, A.; Oueslati, H.; Escudero, D.; Martinez Sagasti, F.; Piacentini, E.; Ramirez Galleymore, P.; Dugernier, T.; Fagnoul, D.; Michaux, I.; Seibert, A.; Reinikainen, M.; Grøfte, T.; Martin-Loeches, I.; Laffey, J.
Source
In: The Lancet Respiratory Medicine . (The Lancet Respiratory Medicine, October 2023, 11(10):894-904)
Subject
Language
English
ISSN
22132619
22132600
22132600